XML 59 R54.htm IDEA: XBRL DOCUMENT
v3.26.1

Collaboration and license agreements - Summarizes the transaction price allocated to performance obligations (Details) - 2025 Novartis License Agreement - USD ($) $ in Thousands | Jun. 30, 2026 | Dec. 31, 2025
--- | --- | ---
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total unearned amount of transaction price | $ 172,546 | $ 178,247
License and research services for named immunology target [Member] |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total unearned amount of transaction price | 6,558 | 7,019
Research services to support immunology license options [Member] |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total unearned amount of transaction price | 80,458 | 85,698
Material right - first immunology license option [Member] |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total unearned amount of transaction price | 49,091 | 49,091
Material right - second immunology license option [Member] |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Total unearned amount of transaction price | $ 36,439 | $ 36,439

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glue_TwoThousandTwentyFiveNovartisLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=glue_LicenseAndResearchServicesForNamedImmunologyTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=glue_ResearchServicesToSupportImmunologyLicenseOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=glue_MaterialRight-FirstImmunologyLicenseOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=glue_MaterialRight-SecondImmunologyLicenseOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |